Open AccessP1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK‐2 INHIBITORS: SAFETY AND TOLERABILITY
Author(s) -
Pullarkat V.,
CruzChacon A.,
Gangatharan S.,
Melnyk A.,
Palumbo G. A.,
Bellini M.,
Tantravahi S. K.,
Qin Q.,
Potluri J.,
Vachhani P.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847148.78233.c8
Subject(s) - medicine , ruxolitinib , tolerability , cohort , myelofibrosis , anemia , adverse effect , clinical endpoint , phases of clinical research , surgery , gastroenterology , bone marrow , clinical trial